High-Flow Oxygen Lowers Intubation but Does Not Improve Survival
High-flow nasal cannula therapy reduces intubation rates in acute hypoxemic respiratory failure without altering 28-day mortality.
Prehospital Whole Blood Shows No Survival Benefit Over Component Therapy
A randomized trial of 616 trauma patients found prehospital whole blood did not reduce 24-hour mortality or massive transfusion needs.
Obinutuzumab Shows High Efficacy in Active Systemic Lupus Erythematosus
A phase 3 trial shows the anti-CD20 antibody obinutuzumab significantly improves clinical responses and reduces flares in active lupus.
Zorevunersen Cuts Convulsive Seizures in Children With Dravet Syndrome
The investigational antisense therapy reduced convulsive-seizure frequency by up to 90.91% and improved adaptive behavior over 36 months.
Finerenone Reduces Albuminuria in Type 1 Diabetes and CKD
A phase 3 trial shows the mineralocorticoid receptor antagonist finerenone safely lowers albuminuria in adults with type 1 diabetes.
Neoadjuvant GOLP Doubles Event-Free Survival in Cholangiocarcinoma
Administering the GOLP regimen before surgery extends median event-free survival to 18 months in high-risk intrahepatic cholangiocarcinoma.
Apixaban Reduces Bleeding Risk Versus Rivaroxaban in Venous Thromboembolism
In a randomized trial of 2,760 patients, apixaban resulted in a 3.3% bleeding rate compared to 7.1% for rivaroxaban over three months.
Romiplostim Prevents Chemotherapy Dose Reductions in Gastrointestinal Cancers
A phase 3 trial shows romiplostim maintains platelet counts, allowing patients to receive full oxaliplatin-based chemotherapy doses.
Inhaled Treprostinil Slows FVC Decline in Idiopathic Pulmonary Fibrosis
A phase 3 trial shows inhaled treprostinil preserves forced vital capacity and reduces clinical worsening over 52 weeks versus placebo.